
Key Points
- 01Gilead (GILD) has reached a national agreement in Canada for public reimbursement of Lyvdelzi (seladelpar)
- 02The deal follows successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance
- 03Public drug plans could start reimbursing eligible PBC patients as early as 2027
- 04Lyvdelzi targets primary biliary cholangitis, a rare chronic liver disease with limited treatments
National reimbursement milestone for Lyvdelzi
Gilead Sciences (GILD) has reached a national agreement on public reimbursement terms for LYVDELZI (seladelpar) in Canada, following successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance. The agreement clears a key national pricing hurdle and enables participating provincial, territorial and federal public drug plans to move toward funding the medicine for eligible patients with primary biliary cholangitis (PBC). Public reimbursement of Lyvdelzi could begin as early as 2027 in some jurisdictions, subject to individual plan decisions on formulary listing and reimbursement criteria.
This national agreement represents a critical step toward making Lyvdelzi a publicly funded treatment option for Canadians living with PBC, a rare and chronic liver disease. With the pCPA negotiations concluded, attention now shifts to the review processes of individual drug plans, which will determine how and when patients can access the therapy through public coverage.
Implications for Canadians living with PBC
PBC is described as a progressive autoimmune condition that damages the bile ducts in the liver, potentially leading to severe liver damage and liver failure if left untreated. The disease can significantly affect quality of life, and symptoms may include cholestatic itch related to impaired bile flow. There is currently no cure for PBC, and existing treatment options have historically been limited, creating an unmet need for additional therapies.
PBC affects approximately 143,000 people in North America and is more common in women. Treatment goals focus on reducing the risk of disease progression and alleviating symptoms related to cholestasis. The effect of therapy is primarily measured by improvement and normalization of liver biochemical tests, particularly alkaline phosphatase levels, which are considered an important marker associated with long-term outcomes in PBC.
Lyvdelzi’s indication and regulatory status
Lyvdelzi (seladelpar) is indicated in Canada for the treatment of primary biliary cholangitis in adults. It can be used in combination with ursodeoxycholic acid (UDCA) in patients with an inadequate response to UDCA alone, or as monotherapy in adults who are unable to tolerate UDCA. This positioning addresses patients who remain insufficiently controlled on current standard therapy or who cannot use it.
The medicine has been granted a Notice of Compliance with conditions, pending results of trials designed to verify its clinical benefit. This conditional regulatory status allows access while additional evidence is generated. The newly secured national reimbursement terms create a pathway for public funding, which patient advocates describe as an important step that can make a real difference for people living with PBC and their families.
Next steps toward public access
With the pan-Canadian negotiations now finalized, each participating provincial, territorial and federal public drug plan will conduct its own review of Lyvdelzi. These reviews will determine whether, and under what conditions, the drug is added to their formularies. Timelines are expected to vary by jurisdiction, but the framework now exists for some plans to begin reimbursing eligible PBC patients as early as 2027.
Stakeholders within the PBC community highlight this development as a pivotal moment for an underserved patient population facing a lifelong, unpredictable disease. Expanded access to innovative medicines through public drug plans is viewed as a way to address the ongoing gap in treatment options for Canadians affected by PBC.
Key Takeaways
- 01Completion of pan-Canadian negotiations moves Lyvdelzi from regulatory approval toward practical, reimbursed access for PBC patients in Canada.
- 02Public coverage will depend on decisions by individual provincial, territorial and federal drug plans, creating a staged timeline for access that may begin in 2027.
- 03The agreement specifically targets patients with inadequate response or intolerance to UDCA, signaling a focus on unmet medical need within the broader PBC population.
References
- https://finance.yahoo.com/healthcare/articles/canadians-living-primary-biliary-cholangitis-120000582.html?.tsrc=rss
- https://rallies.ai/news/gilead-reaches-canadian-public-reimbursement-agreement-for-lyvdelzi-liver-disease-treatment-6270a08214d0665e
- https://www.newswire.ca/news-releases/canadians-living-with-primary-biliary-cholangitis-pbc-one-step-closer-to-new-treatment-option-as-gilead-reaches-milestone-national-agreement-for-lyvdelzi-r-seladelpar--843576822.html